<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml">
  <head>
    
<meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
<title>diaDexus' (CPA) CEO Lori Rafield on Q2 2015 Results - Earnings Call Transcript | Seeking Alpha</title>
<meta name="application-name" content="Seeking Alpha - Read, Decide, Invest."/>
<meta name='viewport' content='width=1300'>


<meta http-equiv="x-dns-prefetch-control" content="on">
<link rel="dns-prefetch" href="//staticseekingalpha.a.ssl.fastly.net">
<link rel="dns-prefetch" href="//staticseekingalpha1.a.ssl.fastly.net">
<link rel="dns-prefetch" href="//staticseekingalpha2.a.ssl.fastly.net">
<link rel="dns-prefetch" href="//staticseekingalpha3.a.ssl.fastly.net">

<link href="//staticseekingalpha2.a.ssl.fastly.net/assets/favicon-46530755d46bb8a9005e583874cd8e5e.ico" rel="shortcut icon" type="image/ico">
<link rel="icon" type="image/png" href="//staticseekingalpha1.a.ssl.fastly.net/assets/favicon-16x16-09faeeb3fe8e97eb4b92edb8f904d792.png" sizes="16x16">
<link rel="icon" type="image/png" href="//staticseekingalpha2.a.ssl.fastly.net/assets/favicon-32x32-2208d73dfe9595e55f907c9ded5cc353.png" sizes="32x32">
<link rel="icon" type="image/png" href="//staticseekingalpha.a.ssl.fastly.net/assets/favicon-96x96-4f389eca45e750f5651a690469eb0af5.png" sizes="96x96">
<link rel="icon" type="image/png" href="//staticseekingalpha3.a.ssl.fastly.net/assets/favicon-192x192-6c9d478d320e913dc8644e519b4c1766.png" sizes="192x192">

<meta name="description" content="diaDexus, Inc. (OTCQB:DDXS) Q2 2015 Results Earnings Conference August 13, 2015, 16:30 PM ET Executives Leone D. Patterson - Chief Financial Officer Lori F. Raf" /><meta name="keywords" content="OTCMKTS:DDXS" /><meta name="news_keywords" content="DDXS, diaDexus Inc., Healthcare, Transcripts, United States, Drug Manufacturers - Other" /><meta name="syndication-source" content="http://seekingalpha.com/article/3438836-diadexus-cpa-ceo-lori-rafield-on-q2-2015-results-earnings-call-transcript"><link rel="canonical" href="http://seekingalpha.com/article/3438836-diadexus-cpa-ceo-lori-rafield-on-q2-2015-results-earnings-call-transcript" />


<script type="text/javascript">window.NREUM||(NREUM={});NREUM.info={"beacon":"bam.nr-data.net","errorBeacon":"bam.nr-data.net","licenseKey":"c0370b1d43","applicationID":"334927,334964","transactionName":"cldeEUAJWgldEBsASkVRUwlXFRkWUA1D","queueTime":2,"applicationTime":71,"agent":"js-agent.newrelic.com/nr-686.min.js"}</script>
<script type="text/javascript">window.NREUM||(NREUM={}),__nr_require=function(e,n,t){function r(t){if(!n[t]){var o=n[t]={exports:{}};e[t][0].call(o.exports,function(n){var o=e[t][1][n];return r(o?o:n)},o,o.exports)}return n[t].exports}if("function"==typeof __nr_require)return __nr_require;for(var o=0;o<t.length;o++)r(t[o]);return r}({QJf3ax:[function(e,n){function t(e){function n(n,t,a){e&&e(n,t,a),a||(a={});for(var u=c(n),f=u.length,s=i(a,o,r),p=0;f>p;p++)u[p].apply(s,t);return s}function a(e,n){f[e]=c(e).concat(n)}function c(e){return f[e]||[]}function u(){return t(n)}var f={};return{on:a,emit:n,create:u,listeners:c,_events:f}}function r(){return{}}var o="nr@context",i=e("gos");n.exports=t()},{gos:"7eSDFh"}],ee:[function(e,n){n.exports=e("QJf3ax")},{}],3:[function(e,n){function t(e){return function(){r(e,[(new Date).getTime()].concat(i(arguments)))}}var r=e("handle"),o=e(1),i=e(2);"undefined"==typeof window.newrelic&&(newrelic=window.NREUM);var a=["setPageViewName","addPageAction","setCustomAttribute","finished","addToTrace","inlineHit","noticeError"];o(a,function(e,n){window.NREUM[n]=t("api-"+n)}),n.exports=window.NREUM},{1:12,2:13,handle:"D5DuLP"}],gos:[function(e,n){n.exports=e("7eSDFh")},{}],"7eSDFh":[function(e,n){function t(e,n,t){if(r.call(e,n))return e[n];var o=t();if(Object.defineProperty&&Object.keys)try{return Object.defineProperty(e,n,{value:o,writable:!0,enumerable:!1}),o}catch(i){}return e[n]=o,o}var r=Object.prototype.hasOwnProperty;n.exports=t},{}],D5DuLP:[function(e,n){function t(e,n,t){return r.listeners(e).length?r.emit(e,n,t):void(r.q&&(r.q[e]||(r.q[e]=[]),r.q[e].push(n)))}var r=e("ee").create();n.exports=t,t.ee=r,r.q={}},{ee:"QJf3ax"}],handle:[function(e,n){n.exports=e("D5DuLP")},{}],XL7HBI:[function(e,n){function t(e){var n=typeof e;return!e||"object"!==n&&"function"!==n?-1:e===window?0:i(e,o,function(){return r++})}var r=1,o="nr@id",i=e("gos");n.exports=t},{gos:"7eSDFh"}],id:[function(e,n){n.exports=e("XL7HBI")},{}],G9z0Bl:[function(e,n){function t(){var e=d.info=NREUM.info,n=f.getElementsByTagName("script")[0];if(e&&e.licenseKey&&e.applicationID&&n){c(p,function(n,t){n in e||(e[n]=t)});var t="https"===s.split(":")[0]||e.sslForHttp;d.proto=t?"https://":"http://",a("mark",["onload",i()]);var r=f.createElement("script");r.src=d.proto+e.agent,n.parentNode.insertBefore(r,n)}}function r(){"complete"===f.readyState&&o()}function o(){a("mark",["domContent",i()])}function i(){return(new Date).getTime()}var a=e("handle"),c=e(1),u=window,f=u.document;e(2);var s=(""+location).split("?")[0],p={beacon:"bam.nr-data.net",errorBeacon:"bam.nr-data.net",agent:"js-agent.newrelic.com/nr-686.min.js"},d=n.exports={offset:i(),origin:s,features:{}};f.addEventListener?(f.addEventListener("DOMContentLoaded",o,!1),u.addEventListener("load",t,!1)):(f.attachEvent("onreadystatechange",r),u.attachEvent("onload",t)),a("mark",["firstbyte",i()])},{1:12,2:3,handle:"D5DuLP"}],loader:[function(e,n){n.exports=e("G9z0Bl")},{}],12:[function(e,n){function t(e,n){var t=[],o="",i=0;for(o in e)r.call(e,o)&&(t[i]=n(o,e[o]),i+=1);return t}var r=Object.prototype.hasOwnProperty;n.exports=t},{}],13:[function(e,n){function t(e,n,t){n||(n=0),"undefined"==typeof t&&(t=e?e.length:0);for(var r=-1,o=t-n||0,i=Array(0>o?0:o);++r<o;)i[r]=e[n+r];return i}n.exports=t},{}]},{},["G9z0Bl"]);</script>
<meta name="apple-mobile-web-app-capable" content="yes">
<meta name="apple-mobile-web-app-status-bar-style" content="black">
<link rel="apple-touch-icon" sizes="57x57" href="//staticseekingalpha3.a.ssl.fastly.net/assets/apple/apple-touch-icon-57x57-a93a575c6dc6cfd0a797599e5a4aca43.png">
<link rel="apple-touch-icon" sizes="72x72" href="//staticseekingalpha2.a.ssl.fastly.net/assets/apple/apple-touch-icon-72x72-83db8db36f683647f2ea4912ef925672.png">
<link rel="apple-touch-icon" sizes="114x114" href="//staticseekingalpha3.a.ssl.fastly.net/assets/apple/apple-touch-icon-114x114-2dc61d132d5605efaec1fbc0f9928d87.png">
<link rel="apple-touch-icon" sizes="144x144" href="//staticseekingalpha.a.ssl.fastly.net/assets/apple/apple-touch-icon-144x144-71696df71f280a287129fa94bed7c653.png">
<link rel="apple-touch-icon" sizes="180x180" href="//staticseekingalpha.a.ssl.fastly.net/assets/apple/apple-touch-icon-180x180-d834ebf09d4ac710eba277348673886f.png">

<meta name="msapplication-config" content="//staticseekingalpha1.a.ssl.fastly.net/assets/ms/browserconfig-3991a8a2de372679027124c341359bf3.xml">
<meta name="msapplication-TileColor" content="#ff7200">
<meta name="msapplication-TileImage" content="//staticseekingalpha3.a.ssl.fastly.net/assets/ms/mstile-144x144-5156f086afb634519136fbe3bb36f435.png">
<link rel="icon" sizes="any" mask href="//staticseekingalpha2.a.ssl.fastly.net/assets/favicon-0e616d30d1102b37d7e06f1a53822ca1.svg">
<meta name="theme-color" content="#ffffff">

<meta property="og:locale" content="en_US">
<meta property="og:site_name" content="Seeking Alpha">
<meta property="og:title" content="diaDexus' (CPA) CEO Lori Rafield on Q2 2015 Results - Earnings Call Transcript">
<meta property="og:url" content="http://seekingalpha.com/earnings_center/all/article/3438836">
<meta property="og:image" content="//staticseekingalpha3.a.ssl.fastly.net/assets/social-50f1e86b5c7a0fda6a96bf2280e5360d.png">
<meta property="og:description" content="diaDexus, Inc. (OTCQB:DDXS) Q2 2015 Results Earnings Conference August 13, 2015, 16:30 PM ET Executives Leone D. Patterson - Chief Financial Officer Lori F. Rafield - Chairman and Chief Executive Officer. William H. Hammond -">

<meta name="twitter:card" content="summary">
<meta name="twitter:site" content="@SeekingAlpha">
<meta name="twitter:title" content="diaDexus' (CPA) CEO Lori Rafield on Q2 2015 Results - Earnings Call Transcript">
<meta name="twitter:image" content="//staticseekingalpha1.a.ssl.fastly.net/images/users_profile/000/101/639/big_pic.png?1361390405">
<meta name="twitter:description" content="diaDexus, Inc. (OTCQB:DDXS) Q2 2015 Results Earnings Conference August 13, 2015, 16:30 PM ET Executives Leone D. Patterson - Chief Financial Officer Lori F. Rafield - Chairman and Chief Executive Offi">

<meta property="fb:admins" content="100006791796236" />

<link href="//staticseekingalpha1.a.ssl.fastly.net/stylesheets/packaged/performance_layout_packaged.css?h=1yw2rdg.css" media="screen" rel="stylesheet" type="text/css" /><link href="//staticseekingalpha.a.ssl.fastly.net/stylesheets/packaged/performance_layout_b_packaged.css?h=1b42syq.css" media="screen" rel="stylesheet" type="text/css" /><link href="//staticseekingalpha3.a.ssl.fastly.net/stylesheets/packaged/article_packaged.css?h=6wcxhb.css" media="screen" rel="stylesheet" type="text/css" />
<!-- BEGIN Krux Control Tag for "seekingalpha.com" -->
<!-- Source: /snippet/controltag?confid=Jubkx3MY&site=seekingalpha.com&edit=1 -->
<script class="kxct" data-id="Jubkx3MY" data-timing="async" data-version="1.9" type="text/javascript">
    window.Krux || ((Krux = function () {
        Krux.q.push(arguments)
    }).q = []);
    (function () {
        var k = document.createElement('script');
        k.type = 'text/javascript';
        k.async = true;
        var m, src = (m = location.href.match(/\bkxsrc=([^&]+)/)) && decodeURIComponent(m[1]);
        k.src = /^https?:\/\/([a-z0-9_\-\.]+\.)?krxd\.net(:\d{1,5})?\//i.test(src) ? src : src === "disable" ? "" :
        (location.protocol === "https:" ? "https:" : "http:") + "//cdn.krxd.net/controltag?confid=Jubkx3MY"
        ;
        var s = document.getElementsByTagName('script')[0];
        s.parentNode.insertBefore(k, s);
    }());
    (function(){
    function retrieve(n){
        var m, k='kx'+n;
        if(window.localStorage){
            return window.localStorage[k] || "";
        }else if(navigator.cookieEnabled){
            m = document.cookie.match(k+'=([^;]*)');
            return (m && unescape(m[1])) || "";
        }else{
            return '';
        }
    }
    Krux.user = retrieve('user');
    Krux.segments = retrieve('segs') && retrieve('segs').split(',') || [];
    })();

</script>
<!-- END Krux Controltag -->





<script type="text/javascript">
  window.PAGE_START_TS = new Date().getTime(); //will be put in mone
  window.primaryMarketCap = 15304658;
  window.primaryTickerSlug = "ddxs";
  var users_on_site='4,567,213';
  var user_cookie={};

  function readCookie(name) {
    var cookie = document.cookie.match(new RegExp('(^|;)\\s*' + escape(name) + '=([^;\\s]*)'));
    return (cookie ? unescape(cookie[2]) : null);
  }

  function addToCookie(key,value) {
    var arr=user_cookie[key].split(',');
    arr.push(value);

    user_cookie[key]=arr.join(',');
  }
  if (readCookie('user_cookie_key')) {
    document.write('<scr'+'ipt src="//staticseekingalpha.a.ssl.fastly.net/account/cookie/'+readCookie('user_cookie_key')+'"></scri'+'pt>');
  } else if (readCookie('user_id')) {
    document.write('<scr'+'ipt src="/account/no_cookie_key"></scri'+'pt>');
  }

  var isThisMyFirstPV = false;
  var _comscore = _comscore || [];
  _comscore.push({ c1: "2", c2: "8500672" });
    (function() {
      var s = document.createElement("script"), el = document.getElementsByTagName("script")[0]; s.async = true;
      s.src = (document.location.protocol == "https:" ? "https://sb" : "http://b") + ".scorecardresearch.com/beacon.js";
      el.parentNode.insertBefore(s, el);
    })();

  var is_pro = false;


  var ASSET_HOSTS = ["//staticseekingalpha.a.ssl.fastly.net","//staticseekingalpha1.a.ssl.fastly.net","//staticseekingalpha2.a.ssl.fastly.net","//staticseekingalpha3.a.ssl.fastly.net"];
</script>
<script crossorigin="use-credentials" src="//staticseekingalpha2.a.ssl.fastly.net/javascripts/packaged/common_packaged.js?h=1rju14v.js" type="text/javascript"></script>
<script crossorigin="use-credentials" src="//staticseekingalpha1.a.ssl.fastly.net/javascripts/packaged/common2_packaged.js?h=lq8ds6.js" type="text/javascript"></script>
<script crossorigin="use-credentials" src="//staticseekingalpha1.a.ssl.fastly.net/javascripts/packaged/coffee_packaged.js?h=1a31cfu.js" type="text/javascript"></script><script crossorigin="use-credentials" src="//staticseekingalpha.a.ssl.fastly.net/javascripts/packaged/common_article_packaged.js?h=jobbp6.js" type="text/javascript"></script>  <script src="//staticseekingalpha.a.ssl.fastly.net/memcached2/symbol_rt_data"></script>

      <script>
      if (!SA.Utils.SASource.didInitialWithEmailInUrl()) {
        document.write('<scr'+'ipt src="//partner.googleadservices.com/gampad/google_service.js" type="text/javascript"></scri'+'pt>');
      }
    </script>
<script>
  var adata = SA.Data.Cache.get('campaign_content');
</script>

        <script id="liftigniter-metadata" type="application/json">
      {
        "author_name": "SA Transcripts",
        "author_image": "//staticseekingalpha1.a.ssl.fastly.net/images/users_profile/000/101/639/big_pic.png?1361390405",
        "id": "3438836",
        "primary_ticker": "ddxs",
        "published_time": "2015-08-13 19:32:05 -0400",
        "publish_time": "2015-08-13 19:32:05 -0400"
      }
    </script>
    <script>
  (function(w,d,s,p,v,e,r) {w['$petametrics_var']=v;w[v]=w[v]||function(){(w[v].q=w[v].q||[]).push(arguments)};w[v].l=1*new Date();e=d.createElement(s),r=d.getElementsByTagName(s)[0];e.async=1;e.src=p;r.parentNode.insertBefore(e,r)})(window,document,'script','//cdn.petametrics.com/p.js','$p');
  $p("init", "k2lfmn21cq6srufb");
  $p("send", "pageview");
</script>
<script type="text/javascript">
  if ((user_email_cookie=readCookie('user_email')) && user_email_cookie.indexOf('@gmail.com')!=-1) {
    createCookie('user_email',(user_email_cookie.replace('@gmail.com','').replace(/\./gi,'').replace(/\+(.*?)$/,''))+'@gmail.com',365);
  }

  if (typeof(readCookie) == "function" && readCookie('user_vocation')) {
    createCookie('u_voc',readCookie('user_vocation'),3000);
  }
  if (readCookie('sapu') == "121") {eraseCookie('sapu');}
  var user_cookie = user_cookie || {};
  eraseCookie("__article_last_size");

if (top.location.pathname == "/" && readCookie('user_id')==957061) {
  var old_SADataCookies = SA.Data.Cookies.get;
  SA.Data.Cookies.get = function(x){if (x=="user_following_users" || x=="user_watchlist_authors") return ""; else return old_SADataCookies(x);}
}
  try{(function(){
    var uc=SA.Data.Cookies.get("user_cookie_key"), t=uc ? uc.match(/t=([0-9]+)/) : null;
    if (t && t[1] < 1367771521) SA.Data.Cookies.set("user_cookie_key","");
  })();} catch(e){}

window.siteon=true;window.acounter=0;//temporary, tell Ilya to delete
</script>
<style>
#embd_slider{
display:none;
}
#top_gainers_wrap .data_currencies_table table {
  width: 100%;
}
#follow_wrap {
  width: 640px;
}

#pro_by_ticker li a {
  max-width:500px;
}
</style> 
<script>
 if (SA && SA.Data && SA.Data.User){
		SA.Data.User.authorResearch = function(){
    return readCookie('author_research_subscriptions') ? readCookie('author_research_subscriptions').split(',') : [];
  }
}
</script>
        </head>
  
  <body class="stretch_bg">

    <script>
  var ms_slug = '';
  var article_dashboards = 'transcript';
  var article_sectors_themes = '@transcripts@us@drug-manufacturers-other@healthcare@article@';
  var ratings_hash={}
  var ARTICLE_ID = 3438836 ;
  var ARTICLE_TYPE = 'transcript';
  var ARTICLE_LOCK = "";
  var availableABVersions=["ver_a"];
  var abOBJ = new ABTest('transcript_pagination', availableABVersions);
  var machine_id = cookieExists('machine_cookie') ? parseInt(readCookie('machine_cookie')) : 0;
  var abVersion = abOBJ.value;
  var sliceSize = 4000;
  var isTranscript = true;
  var insight_sector = null;
  var isWebcast = false;
  var middle_version = ABTest.identity%10;
  var author_tag_id = 96991;
  var author_slug = "sa-transcripts";

  try {window.sessionStorage.setItem("/article/"+ARTICLE_ID, '1');}
  catch (error) {}
</script>
<script>var mone_article_tags = "{ddxs};;;{healthcare};;;{transcripts,us,drug-manufacturers-other};;;{sa-transcripts}"</script>

<script>var ord = Math.floor(Math.random() * 1000000000);</script>
<span class="seeking_alpha_site_title">Seeking Alpha</span>
<script type="text/javascript">
  if (SA.Data.Cookies.get('show_desktop') == '1') {
    var aHTML = [];
    aHTML.push('<div class="mobile_or_full_site">');
    aHTML.push('<span class="mobile_site" onclick="backToMobile();">Click here to view mobile site</span>');
    aHTML.push('<div class="cleaner"></div>');
    aHTML.push('</div>');
    document.write(aHTML.join(""));
  }
  function backToMobile() {
    SA.Data.Cookies.del('show_desktop');
    var url = window.location.href;
    if (url.indexOf('?') > -1){
      url += '&source=show_desktop_false';
    }else{
      url += '?source=show_desktop_false';
    }
    window.location.href = url;
  }
</script>
<div id="header" class="not_logged_in header_nav">
  <div id="logo_and_navigation" class="logo_and_primary_navigation">
    <div id="comment_popup" style="position:relative; left:0; display:none">
  <div id="popup_secondary">
    <div id="inner_popup"></div>
  </div>
</div>    <div class="logo_and_menu_section">
      <div id="header_dropdown">
        <a href="/" id="sa_logo" title="Seeking Alpha" sasource="salogo"></a>
        <div class="header_arrow caret"></div>
        <div class="hdd_wrapper" itemscope="" itemtype="http://schema.org/SiteNavigationElement" role="navigation"><div class="hdd_arrow"></div><ul class="hdd_menu hdd_insights themes"><li class="hdd_header">THEMES</li><li itemprop="name"><a href="http://seekingalpha.com" itemprop="url" sasource="headtab_menu" title="Home">Home</a></li><li class="hdd_sep"></li><li itemprop="name"><a href="http://seekingalpha.com/insight/alternative-investing" itemprop="url" sasource="headtab_menu" title="Alt Investing">Alt Investing</a></li><li class="hdd_sep"></li><li itemprop="name"><a href="http://seekingalpha.com/insight/dividend-investing" itemprop="url" sasource="headtab_menu" title="Dividend Investing">Dividend Investing</a></li><li class="hdd_sep"></li><li itemprop="name"><a href="http://seekingalpha.com/earnings_center" itemprop="url" sasource="headtab_menu" title="Earnings Center">Earnings Center</a></li><li class="hdd_sep"></li><li itemprop="name"><a href="http://seekingalpha.com/etf_hub" itemprop="url" sasource="headtab_menu" title="ETF Hub">ETF Hub</a></li><li class="hdd_sep"></li></ul><ul class="hdd_menu hdd_insights"><li class="hdd_header">&nbsp;</li><li itemprop="name"><a href="http://seekingalpha.com/insight/income-investing" id="income_tab" itemprop="url" sasource="headtab_menu" title="Income Investing">Income Investing</a></li><li class="hdd_sep"></li><li itemprop="name"><a href="http://seekingalpha.com/analysis/investing-ideas" itemprop="url" sasource="headtab_menu" title="Investing Ideas">Investing Ideas</a></li><li class="hdd_sep"></li><li itemprop="name"><a href="http://seekingalpha.com/analysis/macro-view" itemprop="url" sasource="headtab_menu" title="Macro View">Macro View</a></li><li class="hdd_sep"></li><li itemprop="name"><a href="http://seekingalpha.com/analysis/etf-portfolio-strategy" itemprop="url" sasource="headtab_menu" title="Portfolio Strategy">Portfolio Strategy</a></li></ul><ul class="hdd_menu hdd_premium" id="hdd_my_account"><li class="hdd_header">MY ACCOUNT</li><li itemprop="url"><a href="http://seekingalpha.com/account/email_preferences" itemprop="name" sasource="topnav_mouseover" title="Email Settings">Email Settings</a></li></ul><ul class="hdd_menu hdd_premium"><li class="hdd_header">PREMIUM</li><li class="premium_sub_header" itemprop="name"><a href="http://seekingalpha.com/pages/premium_authors" itemprop="url" rel="nofollow" sasource="headtab_menu" title="Premium Authors">Premium Authors</a></li><li><ul class="premium_nav_list"><li itemprop="name"><a href="http://seekingalpha.com/pages/premium_authors?sort=p&amp;order=d" itemprop="url" rel="nofollow" sasource="topnav_mouseover" title="Most Popular">Most Popular</a></li><li itemprop="name"><a href="http://seekingalpha.com/pages/premium_authors?sort=n&amp;order=d" itemprop="url" rel="nofollow" sasource="topnav_mouseover" title="Newest">Newest</a></li></ul></li><li class="hdd_sep"></li><li class="premium_sub_header" itemprop="name"><a href="http://seekingalpha.com/pro/checkout" itemprop="url" rel="nofollow" sasource="headtab_menu" title="PRO">PRO</a></li><li><ul class="premium_nav_list"><li itemprop="name"><a href="http://seekingalpha.com/pro/checkout" itemprop="url" rel="nofollow" sasource="topnav_mouseover" title="Top Ideas">Top Ideas</a></li><li itemprop="name"><a href="http://seekingalpha.com/pro/checkout" itemprop="url" rel="nofollow" sasource="topnav_mouseover" title="First Look">First Look</a></li><li itemprop="name"><a href="http://seekingalpha.com/pro/checkout" itemprop="url" rel="nofollow" sasource="topnav_mouseover" title="Idea Filter">Idea Filter</a></li></ul></li></ul></div>      </div>
      <div class='nav_container_wrap' id='nav_container_wrap'>
  <div id="nav_container" headtab="">
    <div id="navi_cont" >
      <ul id="navi" class="navi">
        <li id='author_research_top_nav' style='display:none'>
          <div id="authors_dropdown">
            <a>My Authors</a>
            <div id="authors_wrapper" class="authors_wrapper"/>
          </div>
        </li>

        <li thistab='portfolio' class="portfolios">
          <a href="http://seekingalpha.com/account/portfolio" sasource="headtabs">Portfolio
            <span id='portfolio_notifications'></span>
          </a>
        </li>
            <li thistab='market_news'>
              <a href="http://seekingalpha.com/news/all" sasource="headtabs">News</a>
            </li>

            <li thistab='analysis'>
              <a href="http://seekingalpha.com/analysis/all" sasource="headtabs">Articles</a>
            </li>

            <li thistab='stocktalks'>
              <a href="http://seekingalpha.com/stocktalks/all" sasource="headtabs">StockTalk</a>
            </li>
        <li thistab='marketplace' id='menu_marketplace_tab'>
          <a href="http://seekingalpha.com/pages/premium_authors" sasource="headtabs" style="display: none" rel="nofollow">Marketplace</a>
        </li>

        <li thistab='pro' class="pro_tab" id="nav_pro_tab">
          <a href="http://seekingalpha.com/account/pro" sasource="headtabs" rel="nofollow">PRO</a>
        </li>

        <li class="right_section">
          <div class="" id="user_settings_wrapper"></div>
        </li>
      </ul>
    </div>
  </div>


  <div style='display:none' class="rta_nav etf_hub">
    <span class="rta_nav_wrap">
      <div>To screen ETFs by asset class, performance, yield and more, check out the <a href="/etf_hub" sasource="etf_performance" >ETF Hub.</a> <a  sasource="etf_performance" href="/etf_hub" id="etf_hub_button">ETF Hub</a></div>
    </span>
  </div>
</div>

    </div>

    <div class="info_and_search_section" id="right_menu">
      <div id="nav_user_settings"></div>
      <div id="site_search">
        <div class="search_box_container_isolated">
  <div class="search_box">
    <form id="search_box_sa_search" method="get" class="linktosym comp search" action="/search/" onsubmit="return false;">
      <fieldset>
        <input type="button" class="search_button" value="" onclick="if ($('autocomplete_sa_search').value!=$('autocomplete_sa_search').title) AutoCompleteSAConfig.Packages.search.Find()" />
        <input id="autocomplete_sa_search" class="input_text text" type="text" value="Search by symbol, author, keyword..." size="25" autocomplete="off" onblur="if($$('.search_box'))$$('.search_box')[0].style.background='';this.style.color=this.value=='' ? '#8D8D8D' : '#000000';handleInput(this,'blur')" onfocus="if($$('.search_box'))$$('.search_box')[0].style.background='#fff';this.style.color='#000000';handleInput(this,'focus')" afteruploadvalue='eFind quotes, people, expressions, transcripts' title='Search by symbol, author, keyword...' class="find_transcripts" />
      </fieldset>
      <input type="hidden" name="source" value="search_general" />
      <input type="hidden" id="autocomplete_sa_hidden_search" name="q" value="" />
      <input type="hidden" id="autocomplete_sa_hidden_avoid_symbol" name="avoid_symbol" value="" />
      <input type="hidden" name="sort" value="date:d" />
      <input type="hidden" name="cx" value="018269914407235029540:cdhc2yeo2ko" />
      <input type="hidden" name="cof" value="FORID:11;NB:1" />
      <input type="hidden" name="goto_search_tab" value="" />
    </form>
    <script type="text/javascript">SeekingAlpha.Initializer.LogAndRun(function () { AutoCompleteSAConfig.Load('search', { Symbols:true, Keywords:true, IframeCover:true, AfterInsert:function () { this.Find(); }, AfterSubmit:function () { this.Find(); }}) });</script>
    <script type="text/javascript" src="//cse.google.com/coop/cse/brand?form=searchbox_018269914407235029540%3Acdhc2yeo2ko&lang=en"></script>
  </div>
</div>

      </div>
    </div>
    <div class="clearfix"></div>
  </div>
  <script type="text/javascript">
      SeekingAlpha.Initializer.LogAndRun(SA.Navigation.Top.init);
  </script>
</div>

<div id="main_container" class="center_pro transcript_page">
    <script>
      if(window.screen.availWidth > 1260 || SA.Utils.Env.isIPad || SA.Utils.Env.isAndroid) $('main_container').addClassName('show_left_cont');
    </script>
     <div class='left_cont'>
            <div id="left_top_ad"></div>
        <div class="stickyad_wrapper">
          <div class="item banner160x600" id="fixed_banner160x600"></div>
					 <script type="text/javascript">
							var didCreateAd = false;
              function setAD(){
               if (didCreateAd) return;

							    SA.Utils.Ads.GoogleTag.define("/6001/sek.earnings/reports", [[160,601]],'left_top_ad', {"sz":"160x601","x":["x","x"],"tile":1,"d":["earnings","sectors"],"t":["reports","transcripts","us","drug-manufacturers-other","healthcare","article"],"aid":3438836,"z":1,"a":"sa-transcripts","cnt":["5","20","23","37"],"pr":"ddxs","s":"ddxs"});

								SA.Utils.Ads.GoogleTag.define("/6001/sek.earnings/reports", [[160,600]],'fixed_banner160x600', {"sz":"160x600","x":["x","x"],"tile":3,"d":["earnings","sectors"],"t":["reports","transcripts","us","drug-manufacturers-other","healthcare","article"],"aid":3438836,"z":1,"a":"sa-transcripts","cnt":["5","20","23","37"],"pr":"ddxs","s":"ddxs"},{sticky: true});

                Mone.article_shown_left_ad = true;
								didCreateAd = true;
              }
              if(window.screen.availWidth > 1260 || SA.Utils.Env.isIPad || SA.Utils.Env.isAndroid) setAD();
           </script>
        </div>
          </div>
  <div id="content_wrapper" itemscope itemtype="http://schema.org/Article" class="article_pages">
    <img src="//staticseekingalpha.a.ssl.fastly.net/images/universal/print_logo.png" width="48" height="20" id="print_seekingalpha_logo" />
     <div id="main_content" class='no_big_gaps_main_content'>
      <div id="" class="no_big_gaps_secondary_ads">
        <div id='article_top_info'>
    <a href='/author/sa-transcripts' sasource='auth_header_pic'><img id='author_info_img' class="author_img" align="center" src="//staticseekingalpha1.a.ssl.fastly.net/images/users_profile/000/101/639/big_pic.png?1361390405" width="66px" height="66px" /></a>
    <div class='info_content'>
      <div>
        <a itemprop="author" class='author_name' href='/author/sa-transcripts' id='author_info_name' rel='author' sasource='auth_header_name'>SA Transcripts</a>,
            <span  >
              <a class='author_nick link' href="http://seekingalpha.com/analysis/transcripts/all?source=article_author_top" target='_blank' onclick='if (!/@seekingalpha.com/.test(SA.Data.User.email())) Mone.event("article", "auth_header_link", "click", {data: {"url":"http://seekingalpha.com/analysis/transcripts/all","text":"Recent earnings call transcripts","author_id":44211,"name":"SA Transcripts","bio":"We cover over 5K calls/quarter"}})'>
                Recent earnings call transcripts
              </a>
            </span>
          <span class="clicks">(44,149 clicks)</span>
      </div>
      <div>
        <span class='author_desc'>We cover over 5K calls/quarter</span>
      </div>
      <div class="bottom_line">
        <a href='/author/sa-transcripts' sasource='auth_header_profile' class="author_action">Profile</a><span class='sep'>|</span>
        <span class='author_action' onclick='Messaging.sendMessagePopup("1aoxskmd","article_auth_header")'>Send Message</span><span class='sep' id='hider'>|</span>
        <div id="mover" class="di">
          <span id="rollover_menu" style="display: none;" onmouseleave="ArticlePage.hideRolloverMenu()">
            <div class="arrow"></div>
            <span id="rollover_content">
              <div class="rta_bottom">
                <div class="m_pop point_left" id="promotion_box_rel">
                  <div id="close_rollover" class="tr cp pr10 pt2">x</div>
                    <div class="m_pop_inner">
                      <div class="popup_header">Author Following Options:</div>

                      <div class="premium_research_header" style='display:none'>
                        <div class="popup_row_header">
                          <div class="preloader_popup_ab" style="float: left;">
                            <input type="checkbox" id="author_research_learn_more" class="author_research_check" style="margin-right: 5px;">
                          </div>
                          
                        </div>
                        <div class="popup_row_footer">
                          &nbsp;<a class="bold" target='_blank' sasource='follow_top_learn_more' href="/account/research/subscribe?slug=sa-transcripts&source=follow_top_learn_more">Learn more»</a>
                        </div>
                      </div>

                      <div class="popup_row_first">
                            <div class="popup_row_header">
                              <div class="preloader_popup_ab" style="float: left;">
                                <input type="checkbox" id="follow_author_checkbox" style="margin-right: 5px;">
                              </div>
                              Follow this author
                            </div>
                          <div class="popup_row_footer">See their articles on your Seeking Alpha homepage and in your feed.</div>
                        </div>
                        <div class="popup_row_second">
                          <div class="popup_row_header">
                            <div class="preloader_popup_ab" style="float: left;">
                              <input type="checkbox" id="get_rta_author_checkbox" style="margin-right: 5px;">
                            </div>
                            <div id="max_rta_header">Real-time alerts on this author</div>
                          </div>
                          <div id="max_rta_footer" class="popup_row_footer">Get their new articles emailed to you as they are published.</div>
                        </div>
                        <div class="popup_row_last">
                          <div class="popup_row_header">
                            <div class="preloader_popup_ab" style="float: left;">
                              <input type="checkbox" id="subscribe_digest" style="margin-right: 5px;">
                            </div>
                            Daily digest on all my authors
                          </div>
                          <div class="popup_row_footer">Get all your favorite authors’ new articles emailed to you in one daily digest.</div>
                        </div>
                    </div>
                  <div class="cleaner"></div>
                </div>
              </div>
            </span>
          </span>
          <span id="msg_popup"></span>
          <span id='follow_btn' class="follow_button_author" onclick="ArticlePage.toogleFollowAuthor('article_auth_header')" onmouseover="ArticlePage.showRolloverMenu()"></span>

          <span id="ballon_container"></span>

          <span id="follow_only_top"></span>
          <span class='clicks'>
            (<span id='follow_clicks' class='follow_clicks_author'>6,668</span> followers)
          </span>
        </div>
      </div>
      <div class='arr_up'></div>
    </div>
    <script>
      setArticleTopABTest();
      SA.Pages.Article.Follow.init('sa-transcripts');


      Mone.articleAuthorLinkShown = true;

      function setEvents(){
        var marketing_unit = $('author_research_learn_more');
        if (marketing_unit) marketing_unit.observe('click', listEvents);
      }

      function listEvents(e){
        if (e.target.hasClassName('author_research_check')){
          SA.Utils.SASource.setNext('follow_top');
          window.open("/account/research/subscribe?slug=sa-transcripts&source=follow_top", '_blank' );
          if (e.target.checked) e.target.checked = false;
        }
      }

      function setArticleTopABTest(){
        if (!window.is_active_research_author || !$('article_top_info') || SA.Data.Cookies.get('author_slug') == window.author_slug) return;

        var test_value = ABTest.tenth, test_version, author_name = $('author_info_name').innerHTML, subscribe_link = '/account/research/subscribe?slug='+ window.author_slug + '&source=article_top_author_banner';
        $$('#article_top_info .info_content div')[0].update($('author_info_name').cloneNode(true));

        if (test_value){
          test_version = 'ver_1';
          $$('#article_top_info .info_content div')[0].insert("<a class='premium_research_button' href='"+subscribe_link+"'>Premium Research &raquo;</a>");
        }
        $('article_top_info').addClassName(test_version);
      }

      SeekingAlpha.Initializer.onDOMLoad(function(){ setEvents();});

    </script>
</div>




      </div>
       <div id='top_author_details'>
         <div id="article_header" class="article_content">
  <div class="top_content">
    <div id="page_header" class="page_header_email_alerts">
      <h1>
        <span itemprop="headline">diaDexus&#x27; (CPA) CEO Lori Rafield on Q2 2015 Results - Earnings Call Transcript</span>
              </h1>
      <div id="article_info">
        <div class="article_info_pos">
          <span itemprop="datePublished" content="2015-08-13T23:32:05Z">Aug. 13, 2015  7:32 PM ET</span>
          <span id='title_article_comments'></span>
          <span class="print_hide"><span class='print_hide'>&nbsp;|&nbsp;</span> <span>About:</span> <span id='about_primary_stocks'><a href="/symbol/DDXS" title='diaDexus, Inc.' sasource='article_primary_about_trc'>diaDexus, Inc. (DDXS)</a></span></span>
          <span class="author_name_for_print">by: SA Transcripts</span>
            <span id="second_line_wrapper"></span>
        </div>
        <div class="article_disclosure">
          <div id="article_body_top2" class="disclosure_top" style="display:none;"></div>
        </div>
      </div>
    </div>
  </div>
</div>
<div class="cleaner"></div>

       </div>
        <div id="article_body_container" class="no_big_gaps_article_body_container">
          <div id="article_body" itemprop="articleBody">
            <div id="article_participants" class="content_part hid">
  <p><strong>Executives</strong></p>
<p>Leone D. Patterson - Chief Financial Officer </p>
<p>Lori F. Rafield - Chairman and Chief Executive Officer.</p>
<p>William H. Hammond - Vice President of Sales</p>
<p><strong>Analysts</strong></p>
</div>

<div id="article_content" class="content_part hid">
  <p>diaDexus, Inc. (<a href='http://seekingalpha.com/symbol/ddxs' title='diaDexus, Inc.'>OTCQB:DDXS</a>) Q2 2015 Results Earnings Conference August 13, 2015  4:30 PM ET</p><p><strong>Operator</strong></p>
<p>Good day ladies and gentlemen, and welcome to the diaDexus, Incorporated Second Quarter 2015 Financial Release Conference Call. At this time, all presentation in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will follow at that time [Operator Instructions] As a reminder this call is being recorded.</p>
<p>I would now like to introduce your host for today's conference Leone Patterson, Chief Financial Officer. You may begin.</p>
<p><strong>Leone D. Patterson</strong></p>
<p>Thank you Kat and good afternoon everyone. We just issued a press release with our financial results for the second quarter 2015, which is available on our new corporate website at www.diadexus.com. With me today are Dr. Lori Rafield, Chairman and CEO and Hodi Hammond, Vice President of Sales. Following our prepared remarks, we will open the lines for questions.</p>
<p>Before I begin our formal remarks, let me remind you that we will be making forward-looking statements including plans and expectations for our products and pipeline, plans for listing to NASDAQ, market opportunities, financial guidance, regulatory submissions, and execution by a new leadership team all of which involves certain assumptions risks and uncertainties and could cause our actual results to differ materially from these statements. A description of these risks can be found in our latest SEC disclosure documents including our Form 10-K, From 10-Q and today's press release. </p>
<p>With that, I’ll turn the call over to Lori.</p>
<p><strong>Lori F. Rafield</strong></p>
<p>Good afternoon and thank you for joining us for our second quarter 2015 financial results conference call. On today's call, we will review our financial performance for the second quarter of 2015 and provide an overview of recent corporate achievements and plans. We will also be providing an update on our ongoing commercial initiatives.</p>
<p>We recently achieved several key milestones and corporate objectives that we believe establish a path towards accelerated revenue growth for the company. First, Hodi Hammond was recently appointed VP of Sales. Hodi brings to us extensive experience in commercial strategy in sales within the diagnostic market, and he has the deep understanding of the commercial channels that are important to diaDexus.</p>
<p>His expertise in developing relationships with accountable care organizations and integrated delivery networks will be invaluable and we welcome him to the team. I would be turning the call over to Hodi shortly and he will be providing a detailed commercial update, including an overview of our new focus on hospitals and hospital networks as a source of untapped growth for our PLAC franchise.</p>
<p>We also recently announced a new collaboration with the Mayo Clinic surrounding our new PLAC activity test. Under this partnership diaDexus and the Mayo Clinic will work together to properly integrate Lp-PLA2 activity testing inter-clinical practice at Mayo. Once fully integrated, the test will be available to patients and providers worldwide through Mayo Clinic’s reference laboratory, which offers advanced laboratory testing in pathology services to more than 5000 healthcare organizations. Mayo has been strong supporter of the value of the information generated from the PLAC activity test and we look forward to working with them on this important initiative.</p>
<p>In addition to the Mayo, we have signed an additional PLAC activity agreement with the University of Oklahoma. This partnership was the result of our relationship with key opinion leader and biomarker researcher Dr. Kenneth Glic, who is also a strong advocate for the importance of the information that PLAC activity provides. And finally on the corporate front, we recently completed one for 15 reverse stock splits. We believe this reverse split is a critical step toward our NASDAQ up listing and is part of our larger strategic initiative to increase awareness and visibility for diaDexus.</p>
<p>For those of you who might be knew the story, I would like to provide a brief overview of our business. PLAC ELISA is our first commercial product, which has been on the market for approximately 10 years. It measures the concentration of circulating Lp-PLA2 in the glide and aids physicians in accessing risk for both coronary heart diseases in patients who have not had prior coronary event and in ischemic stroke in patients with atherosclerosis. PLAC ELISA is an important product for diaDexus as it provides a solid foundation to top line revenue growth and important cash flow.</p>
<p>PLAC Activity is our newest Lp-PLA2 test. It was cleared for market by the FDA in December 2014 and recently launched by diaDexus. New thinking junction with clinical evaluation and patient risk assessment, PLAC Activity aids the physician and predicting risk of CHD in patients with no prior history of cardiovascular events. This is an important distinction, because approximately 75% of CHD patients the vast majority have no history of cardiovascular events. Our launch activities to-date have been largely focused around introducing the test to KLLs at academic hospitals working to secure partnership with these academic hospitals and generally educating and driving awareness about this new test.</p>
<p>In our heart failure franchise, we continue to advance proADM the lead by our market from our pre commercial pipeline. ProADM has entered development on the ELISA platform, which is the fastest establish path to FDA regulatory clearance for novel heart failure biomarkers. We are currently preparing to initiate discussions with the FDA in the fall of 2015 and we remain on track to file a 510(NYSE:<a href='http://seekingalpha.com/symbol/k' title='Kellogg Company'>K</a>) regulatory submission in early 2016.</p>
<p> In addition proADM on the ELISA platform, we are also developing a proADM point-of-care product. Feasibility testing is complete and we are currently assembling development plans to commercialized this test. In our clinical services business, we continue to seek potential partners that are developing therapies for indications for cardiovascular risk information would provide valuable insights. </p>
<p>I will now turn the call over to Hodi to review our commercial business in more detail. Following his and Leone’s update, I will provide summary remarks and then open the line for Q&amp;A. Hodi.</p>
<p><strong>William H. Hammond</strong></p>
<p>Thank you, Lori. diaDexus products are targeted towards providing physicians with information to help better manage of their patients with a broad spectrum of cardiovascular disease conditions. Over last several months, there have been multiple product approvals for new cardiovascular drugs, which underscore the continued interest in this therapeutic area.</p>
<p>First I will provide an overview of the PLAC ELISA business. diaDexus has been successfully selling PLAC ELISA to physicians through our specialty lab reference and national partners for over a decade. PLAC ELISA is the only blood test cleared by the FDA to aid in accessing the risk for both coronary heart disease and ischemic stroke in patients with atherosclerosis.</p>
<p>Interest in the PLAC ELISA test remains high, but the cardiovascular specialty lab channel has been experiencing significant challenges recently with one of the largest labs Health Diagnostic Laboratory or HDL filing for bankruptcy and other cardio specialty labs struggling to find growth avenues.</p>
<p>It’s also well known that obtaining reimbursement coverage from the commercial payers is a challenge, yet in spite of these challenges, the diaDexus sales team has been able to stabilize losses, add new business and main solid foundation revenue levels and important cash flow for the company.</p>
<p>Looking forward, we have several key initiatives that we’ll be implementing, which we believe will help accelerate the revenue growth. As we move into the second half of 2015, we have separated the sales force to focus on either the commercial lab or hospital channel. The existing sales force which we call the lab team will focus on PLAC ELISA and will continue to emphasis on maintaining and expanding relationships with specialty reference and national labs.</p>
<p>We’ve already began hiring an additional small that focused sales force, the hospital team, which will be solely dedicated to selling PLAC Activity. The PLAC Activity. Can be run on automated lab systems, a significant advantage from PLAC ELISA.</p>
<p>Therefore the PLAC Activity force will focus their efforts on selling this test to the hospital market, a diversified channel which includes Integrated Health Systems, Accountable Care Organizations also known as ACOs, the veteran’s health administration, the Department of Defense, and large and small physician group practices.</p>
<p>It’s currently estimated that over 70% of physicians are now employed by hospitals and our goal is to identify and educate those physicians, so that they can begin to drive demand for PLAC Activity that their hospitals. </p>
<p>The Mayo Clinic and University of Oklahoma collaborations, which Lori mentioned earlier, are the first examples of our refined strategy, which targets the hospital channel. We believe both collaborations demonstrate the significant interest in PLAC Activity from both key opinion leaders and the border scientific and medical community.</p>
<p>There are few other initiatives designed to accelerate sales of our PLAC franchise that I would like to highlight. In June, we successfully launched PLACactivity.com, this website serves as a clinical knowledge portal and features annotated publications, expert commentary, regulatory updates and multimedia platforms like video concert to educate physicians, laboratory professionals and patients about the clinical value of the test.</p>
<p>Later this year, we are looking forward to the publication of the results of the regard study. The validation study which was used to obtain FDA clearance for PLAC Activity. This study looked at nearly 4600 individuals with no prior history of cardiovascular events and demonstrated that a high PLAC Activity versus a low PLAC Activity showed a greater hazard ratio for predicting subsequent coronary heart disease and then nearly all other established cardiovascular risk factors including LDL, HDL, age and hypertension.</p>
<p>These results were statically significant within each gender and race analyzed independently. As many of you know, validating clinical data is the cornerstone of any diagnostic technology and is critical to gaining both critical acceptance, and market uptick for a new test like PLAC Activity. This will be the first publish data for the PLAC franchise in several years and it will be a key component of our sales and education efforts.</p>
<p>So in closing, there are numerous potential customers of the PLAC test and we believe the implementation of two highly focused sales organizations is an important step toward maximizing the value of both the PLAC ELISA and the PLAC Activity test. There is lot of work ahead, but that said, I’m confident that we can achieve commercial success with our PLAC franchise and we look forward to achieving this in the months ahead and the quarters ahead. </p>
<p>So with that, now let me turn it over to Leone Patterson, our Chief Financial Officer.</p>
<p><strong>Leone D. Patterson</strong></p>
<p>Thank you, Hodi. I’ll provide an overview of our year-to-date results. Total revenues or the six months ended June 30, 2015, were$10.1 million compared to $13.1 million for the six months ended June 2014. This decrease is primarily due to lower PLAC ELISA product sales and a decrease in service revenues related to GSK agreement, which completed during the fourth quarter of 2014.</p>
<p>Total product sales for the six months ended June 30, 2015, were $10 million compared to $11.6 million for the six months ended June 30, 2014. This $1.6 million decrease is primarily due to a $2.7 million decrease and PLAC ELISA sales to our specialty lab customers but partially offset by $1.1 million increase in PLAC ELISA sales to our national and regional labs.</p>
<p>Of the $2.0 million decrease in sales to specialty labs, $2 million is due to our largest customer HDL filing for bankruptcy in June 2015. Subsequent to HDL’s bankruptcy filing, they have continued to place orders with the company on a cash-in-advance basis. </p>
<p>Total operating cost and expenses for the six months ended June 30, 2015 were $13.5 million compared to $17.2 million for the six months ended June 30, 2014. This translates to a reduction of approximately 22%, which was primarily due to lower research and development expenses related to the B.R.A.H.M.S. Thermo Fisher license agreement for the company’s three heart failure biomarkers. </p>
<p>In addition, there was reduced personnel expenses due to the first half of 2015 resulting from the restructuring implemented in the fourth quarter of 2014. These decreases were partially offset by $0.9 million of provision for doubtful accounts related to outstanding receivables associated with HDL’s bankruptcy, we do intend to file a claim to recover those receivables but their prediction under the bankruptcy filing this amount has been considered uncollectable for accounting purposes.</p>
<p>The company’s net loss for the six months ended June 30, 2015 was $4.3 million or $1.13 per share compared to a net loss of $4.5 million or $1.24 per share for the six months ended June 30, 2014. Cash and cash equivalents at June 30, 2015 were $12.1 million compared to $14.9 million at December 31, 2014. </p>
<p>As we look forward due to our largest customer HDL filing for bankruptcy and the accompanying uncertainty around their ongoing business operations, we are rescinding our previously stated revenue guidance for 2015 and will not be providing an outlook for 2015 at this time.</p>
<p>As mentioned previously, HDL continues to place orders on a cash advance basis, but going forward there is uncertainty regarding their ability to continue these orders given the bankruptcy filing along with their announced company sale process. However, excluding HDL, we are seeing growth overall in the business year-to-date 2014 to 2015 led by our national and regional labs trending at approximately 76%, we expect that growth to continue as we execute on our strategy and diversify our customer base.</p>
<p>Operating cost and expenses are expected to increase in the second half of 2015, this expected increase is primarily due to ongoing investments in the PLAC business to develop the new hospital channel and drive physician demand for PLAC activity, advancing the development of proADM ELISA towards FDA submission in early 2016 and lastly the development of proADM point-of-care. We will continue to closely manage our expenses as we work towards our goal of significantly reducing our 2015 operating cost versus 2014.</p>
<p>Now I would turn the call back to Lori.</p>
<p><strong>Lori F. Rafield</strong></p>
<p>We are very pleased with the progress we have made during the first half of 2015, we continue to expand the leadership team and adding Hodi to the team this quarter was a critical step in executing our larger commercial strategy aimed at accelerating revenue growth. We are actively engaged in activities designed to maximize our two commercial products PLAC ELISA and PLAC Activity.</p>
<p>We believe there is a significant untapped market opportunity for the PLAC franchise and we are working to accelerate growth of PLAC with a focus on driving activity through new channels of potential customers. On top of the financial foundation that PLAC provides having a high value biomarker in heart failure allows diaDexus to tap into a huge opportunity and potentially help manage patients suffering from acute heart failure episodes.</p>
<p>We are rapidly advancing our lead pipeline asset proADM ELISA and we are on track to submit a 510(<a href='http://seekingalpha.com/symbol/k' title='Kellogg Company'>K</a>) regulatory filing early in 2016. Assuming FDA clearance we could have our third commercial product next year. Behind proADM ELISA the proADM point-of-care product is completing feasibility. </p>
<p>On the corporate front, we are actively working toward an up listing to the NASDAQ, we believe this will increase visibility and awareness of the company, improve our access to capital and improve liquidity for our shareholders. In closing, we believe our assets have substantial commercial potential that is yet to be unlocked and we see multiple opportunities to drive top line revenue growth.</p>
<p>We realize there is substantial work ahead especially given the challenges in the cardiovascular labs channel. However, with PLAC Activity we now have an opportunity to accelerate growth through the new hospital channel and directly drive demand for this new test. We will continue executing on our strategy of diversifying our customer base and product pipeline and we will strive to maintain the momentum we've created in the last few months.</p>
<p>We look forward to updating you on our progress in future calls and with that we would be happy to take your questions.</p>
</div>

<div id="article_qanda" class="content_part hid">
  <p><strong>Question-and-Answer Session</strong></p>
<p><strong>Operator</strong></p>
<p>Thank you. [Operator Instructions] And our first question comes from the line of [indiscernible]. Your line is open. Please go ahead.</p>
<p><strong><span class="question">Unidentified Analyst</span></strong></p>
<p>Good afternoon everyone. </p>
<p><strong><span class="answer">Lori F. Rafield</span></strong></p>
<p>Hi Ben.</p>
<p><strong><span class="question">Unidentified Analyst</span></strong></p>
<p>Just curious on HDL, when did you go to cash terms with them or cash-in-advance terms and what were the prior terms there?</p>
<p><strong><span class="answer">Leone D. Patterson</span></strong></p>
<p>Hi this is Leone the CFO. So we at the time when they filed for bankruptcy on June 7, we actually opportunistically had a phone call with them exactly that same day and we were able to head the conversation with them that they had expressed an interest to continue to place orders. However, given the receivable they had outstanding, we told them at that time that we would only accept cash-in-advance orders. So that happened at the time when we all found out that they filed for bankruptcy.</p>
<p><strong><span class="question">Unidentified Analyst</span></strong></p>
<p>Okay. So sales associated with the provision for doubtful accounts could have generated in April and May?</p>
<p><strong><span class="answer">Leone D. Patterson</span></strong></p>
<p>So there is two components, one is that we had an outstanding receivable at the time of filings, that had to do with orders that they have placed through the first quarter and they will also placed order in April and May. We had to book a receivable for the outstanding balance that was still outstanding at the end of June 7 related to receivable at March and then we reversed the revenues associated with April and May order because of the uncollectability of those revenues </p>
<p><strong><span class="question">Unidentified Analyst</span></strong></p>
<p>So some of the sales would have taken place in Q1 </p>
<p><strong><span class="answer">Leone D. Patterson</span></strong></p>
<p>There were some sales in Q1, but they have been, they are reflected in these numbers as revenues, because we did not know about the bankruptcy filing until after we had filed a 10-Q for Q1.</p>
<p><strong><span class="question">Unidentified Analyst</span></strong></p>
<p>Can you kind of break that down, I mean we are third of them in Q1 and the balance in Q2 or…</p>
<p><strong><span class="answer">Leone D. Patterson</span></strong></p>
<p>What I can say is that much of the revenues year-to-date for HDL were from the first quarter, there were revenues as I mentioned that we booked subsequent to them filing, they did purchase orders from - made orders for that subsequent to that from June 7 through to the end of the quarter, but majority of those revenues were in Q1.</p>
<p><strong><span class="question">Unidentified Analyst</span></strong></p>
<p>Okay, that’s helpful and then any chance you have and I could probably back into it once you file the Q, but what is the year-over-year growth rate might have been excluding HDL for either the quarter or for six months.</p>
<p><strong><span class="answer">Leone D. Patterson</span></strong></p>
<p>So definitely excluding HDL there is revenues that we believe that the business is growing without HDL, I don’t think would percentage, but I can tell you that it was [indiscernible] without HDL.</p>
<p><strong><span class="question">Unidentified Analyst</span></strong></p>
<p>Okay. And then…</p>
<p><strong><span class="answer">Leone D. Patterson</span></strong></p>
<p>Sorry to finish off. As we represented in the National and regional labs, there was significant growth that occurred with the national and regional labs year-over-year, which was the reason why overall there was an increase in the business year-over-year, year-to-date.</p>
<p><strong><span class="question">Unidentified Analyst</span></strong></p>
<p>Okay. And then no change to pricing or anything like that?</p>
<p><strong><span class="answer">Leone D. Patterson</span></strong></p>
<p>We continue to review our contract with all our customers to look at what would be the respected price base over there on the contract negotiations and status of the exploration or not and so we were looking that with all our customers and including HDL.</p>
<p><strong><span class="question">Unidentified Analyst</span></strong></p>
<p>Okay. And I mean is there room - is that trending upper or down do you think?</p>
<p><strong><span class="answer">Leone D. Patterson</span></strong></p>
<p>I would say that’s trending up.</p>
<p><strong><span class="question">Unidentified Analyst</span></strong></p>
<p>Okay.</p>
<p><strong><span class="answer">Leone D. Patterson</span></strong></p>
<p>From the ever sales…</p>
<p><strong><span class="question">Unidentified Analyst</span></strong></p>
<p>Okay. Good. And then on the new sales strategy, how big is each group going to be and I guess what are kind of the plan of attack there, I know some of it was covered earlier.</p>
<p><strong><span class="answer">Lori F. Rafield</span></strong></p>
<p>Yes. I mean, this is Lori, Ben. What we can say right now is that each sales force is going to be 10 or less people, I think part of it is like we’ve articulated throughout the year, the activity launch is very focused. That sales force is less territorial lead divided up compared to the lab channel, simply because it’s a new product launch for us and we know exactly where we need to go particularly with Hodi joining us in order to drive sales and the people that are being hired have the relationships with our targeted customers. So for now, I think we are comfortable saying is it’s less than 10 people in each sales force.</p>
<p><strong><span class="question">Unidentified Analyst</span></strong></p>
<p>Okay. That’s helpful. And then you mentioned in the press release and earlier on the call that, you conducted this primary market research on primary care physicians, </p>
<p><strong><span class="answer">Lori F. Rafield</span></strong></p>
<p>Yup.</p>
<p><strong><span class="question">Unidentified Analyst</span></strong></p>
<p>Can you share any color on those specific findings that came out of that?</p>
<p><strong><span class="answer">Lori F. Rafield</span></strong></p>
<p>What I will say Ben is that the primary market research supports what we have believed for quite some time, which is there is interest substantial interest particularly from the primary care physicians to have access to the information that the PLAC test provides. To us, what that means is as we’ve also been saying 80% of this market is served through the hospital and hospital channel and we needed PLAC Activity to do that. </p>
<p>And then we needed somebody running the sales organization that had these relationships to be able to quickly start to penetrate the market. And so the market research has confirmed that there is demand, which we have already seen for the test by the primary care doc and we believe that we can grow the commercial opportunity for the Lp-PLA2 biomarker substantially over the next few years.</p>
<p><strong><span class="question">Unidentified Analyst</span></strong></p>
<p>Okay. And then lastly from me, when do you expect the full integration to occur with Mayo Medical Labs?</p>
<p><strong><span class="answer">Lori F. Rafield</span></strong></p>
<p>Maybe you could define for me Ben, what full integration mean.</p>
<p><strong><span class="question">Unidentified Analyst</span></strong></p>
<p>Well, it says in the press release once fully integrated I guess what’s your definition?</p>
<p><strong><span class="answer">Lori F. Rafield</span></strong></p>
<p>So right now, what we have is an integrated marketing and sales effort with the Mayo right now. We’ve already conducted a joint symposium with them and we are in the process of really rolling out the test to all of the size for the Mayo Medical Labs.</p>
<p><strong><span class="question">Unidentified Analyst</span></strong></p>
<p>Okay. Great. Thank you very much.</p>
<p><strong><span class="answer">Lori F. Rafield</span></strong></p>
<p>Thank you.</p>
<p>End of Q&amp;A</p>
<p><strong>Operator </strong></p>
<p>And I’m showing no further questions at this time. I’ d like to turn the call back to Lori Rafield, Diadexus’s CEO, for any closing remarks.</p>
<p><strong>Lori F. Rafield</strong></p>
<p>Thank you for dialing in today and asking thoughtful questions. Please feel free to contact us if you have any further questions.</p>
<p><strong>Operator</strong></p>
<p>Ladies and gentlemen, thank you for participating in today’s conference. This concludes today’s program. You may all disconnect, everyone have a great day.</p>
</div>

<div id="article_disclaimer" class="content_part hid">
  
<p><strong>Copyright policy: </strong>All transcripts on this site are the copyright of Seeking Alpha. However, we view them as an important resource for bloggers and journalists, and are excited to contribute to the democratization of financial information on the Internet. (Until now investors have had to pay thousands of dollars in subscription fees for transcripts.) So our reproduction policy is as follows: <strong>You may quote up to 400 words of any transcript on the condition that you attribute the transcript to Seeking Alpha and either link to the original transcript or to www.SeekingAlpha.com. All other use is prohibited.</strong></p>

<p>THE INFORMATION CONTAINED HERE IS A TEXTUAL REPRESENTATION OF THE APPLICABLE COMPANY'S CONFERENCE CALL, CONFERENCE PRESENTATION OR OTHER AUDIO PRESENTATION, AND WHILE EFFORTS ARE MADE TO PROVIDE AN ACCURATE TRANSCRIPTION, THERE MAY BE MATERIAL ERRORS, OMISSIONS, OR INACCURACIES IN THE REPORTING OF THE SUBSTANCE OF THE AUDIO PRESENTATIONS. IN NO WAY DOES SEEKING ALPHA ASSUME ANY RESPONSIBILITY FOR ANY INVESTMENT OR OTHER DECISIONS MADE BASED UPON THE INFORMATION PROVIDED ON THIS WEB SITE OR IN ANY TRANSCRIPT. USERS ARE ADVISED TO REVIEW THE APPLICABLE COMPANY'S AUDIO PRESENTATION ITSELF AND THE APPLICABLE COMPANY'S SEC FILINGS BEFORE MAKING ANY INVESTMENT OR OTHER DECISIONS.</p>
<p>If you have any additional questions about our online transcripts, please contact us at: <a href="mailto:transcripts@seekingalpha.com" rel="nofollow"><u>transcripts@seekingalpha.com</u></a>. Thank you!</p>

</div>

<div id="article_slice"></div>

<div class="cleaner"></div>

          </div>
          <div class="cleaner"></div>
          <div id="trafic_driver_alt_invest">
            <script>SA.Utils.Ads.marketing("trafic_driver_alt_invest", 'articles', 1, {"aid":3438836,"d":["sectors"],"t":["transcripts","us","drug-manufacturers-other","healthcare","article"],"s":["ddxs"],"pr":"ddxs","z":1,"a":"sa-transcripts","cnt":["5","20","23","37"],"ldr":[]});</script>
          </div>
          <div class="cleaner"></div>
          <div class="transcript_bottom_tabs">
            <ul id="tab_cmd" style="float:left;display:none;">
              <li id="tab_single_bottom" name="tab_single" style="border-width:0px !important;" onclick='singlePageView()'><span>Single page view</span></li>
              <li id="tab_search_bottom" class="last chosen" name="tab_search" style='display:none;border-left: 1px solid #C4C4C4;'><span>Search</span></li>
            </ul>
            <div id="pag_cmd" style="display:none;">
            	<div id="tab_prev_bottom" name="tab_prev" style="display:none;float:left"><a href="javascript:void(0)" onclick="abOBJ.convert('Prev Page');trascriptNextSlice(-1)">&laquo; Previous</a>&nbsp;|&nbsp;</div>
            	<div id="tab_pagination" style="float:left"> page <span id="current_page_index">1</span> / <span id="last_page_index"></span></div>
            	<div id="next_page" style="display:none;">|&nbsp;<a href="javascript:void(0)" onclick="abOBJ.convert('Next Page');trascriptNextSlice(1)">Next »</a></div>
            </div>
            <div class="cleaner"></div>
          </div>
          <script>OpenTranscriptPage();</script>
          <div id="content_follow_up" class="transcript_follow_up">
            <div id="paging" class="transcript-paging"></div>
            <div id="article_bottom_about" class="article_bottom_units"></div>
            <div id="pro_by_ticker"></div>

            <div class="share_this_page_article_bottom">
              <ul id="page_toolbar" class="page_toolbar">
  <li class="share_this_page_article_toolbar">
    <div class="share_this_page_snippet">
  <div id="first_line_info" style="width:490px">
    <div class="left"><h6><span id="share_slogan" class="fs16">Share this transcript with a colleague</span></h6></div>
  </div>
  <div class="widgets">
    <!-- Email -->

      <span class="email_this" onclick="email_story_to_friends('Article',3438836,'http://seekingalpha.com/article/3438836-diadexus-cpa-ceo-lori-rafield-on-q2-2015-results-earnings-call-transcript')">
        <div class="email_button"></div>
        <div class="email_bubble">
          <span id="widget_email_count"></span>
          <span class="cor_right"></span>
        </div>
      </span>
    <!-- twitter -->
    <span class="twitter_small">
        <a href="https://twitter.com/share" class="twitter-share-button twitter_share" data-text="diaDexus&#x27; (CPA) CEO Lori Rafield on Q2 2015 Results - Earnings Call Transcript http://seekingalpha.com/article/3438836-diadexus-cpa-ceo-lori-rafield-on-q2-2015-results-earnings-call-transcript?source=tweet $DDXS" data-related="salphatrending" data-url=" " data-counturl="http://seekingalpha.com/earnings_center/all/article/3438836" data-count="horizontal">Tweet</a>
    </span>
    <!-- Linked In -->
      <span id="linkedin_1" class="linkedin_small linkedin_share"><script type="IN/Share" data-counter="right" data-onsuccess="linkedin_callback" data-url="http://seekingalpha.com/earnings_center/all/article/3438836?source=linkedin_share"></script></span>
    <!-- facebook -->
    <span id="span_fb_widget_like" class="facebook_small facebook_share"><div class="fb-like" data-href="http://seekingalpha.com/earnings_center/all/article/3438836?source=facebook" data-send="false" data-layout="button_count" data-show-faces="false" data-font="tahoma"></div></span>
    <div id="span_fb_widget_share" style="display: none;margin:0 10px 0 0;" class="fb-like fl" data-href="http://seekingalpha.com/earnings_center/all/article/3438836?source=facebook" data-layout="button" data-action="like" data-show-faces="false" data-share="false"></div>
    <!-- Plusone  -->
      <span id="pluszone" class="plusone_wrap"><span class="plusone plusone_share"><div class="g-plusone" data-size="medium" annotation="bubble" data-width="65" data-callback="plusone_callback"></div></span></span>
    <!-- print -->
      <span class="print_this" onclick="print_article('with_comments')"><Print><div class="print_button"></div></span>
  </div>
</div>

  <script>
     //FB Share button test
     $('span_fb_widget_like').hide();
     $('span_fb_widget_share').show();
     setTimeout(function(){$('span_fb_widget_share').style.background="none";}, 15000);
     $('pluszone').setStyle({'margin-left':'5px'});


    SeekingAlpha.Initializer.AddAfterLoad(function(){
      new Ajax.Updater({success: 'widget_email_count'}, '/form/ajax_get_email_count', {
        method: 'get',
        parameters: {
          item_name: 'Article',
          article_id: '3438836'
        }
      });
    });

  </script>

  </li>
</ul>
            </div>
            <div class="cleaner"></div>
            <div class="comments_with_more">
              <div id="comments_section">
              </div>
            </div>

            <div id="bottom_rta_unit" class="cb"></div>

          </div>
        </div>
    </div>
<div class="article_right_content">
	  <div id="ads_and_tools" class="article_sidebar_tools red_sidebar">
    <div id='earnings_sticky'>
    	<div class="insight_back_link">
      	Back to:<br/>
      	<a href="/earnings_center/transcripts" sasource="earnings_back_link">
        	EARNINGS TRANSCRIPTS &raquo;
      	</a>
    	</div>
			<div id='ad_earnings_sticky'></div>
				<script>
				if (!is_pro){
					SA.Utils.Ads.GoogleTag.define("/6001/sek.earningscenter/articles", [[300,250],[300,600]],'ad_earnings_sticky', {"sz":"300x250,300x600","x":"x","tile":2,"d":["earningscenter","sectors"],"pos":"t","t":["articles","transcripts","us","drug-manufacturers-other","healthcare","article"],"aid":3438836,"z":1,"a":"sa-transcripts","cnt":["5","20","23","37"],"pr":"ddxs","s":"ddxs"},{sticky: true});
				}
			</script>
  	</div>
	</div>
<script>
    if($$('#ads_stick .banner300x600')[0] && $('article_body_container').offsetHeight>1400) {
        if (SA.Data.User.loggedIn()) new stickyAd('ads_stick', {remove_stick_top: 650}).fixed_ads_init();
    }
</script>

</div>

  </div>
  <input id="short_url" type="hidden" value="http://seekingalpha.com/a/21pf8" />
</div>
<div id='footer_break'><div></div></div><div id="footer">
  <div id="footernav">
    <div class="footernav_left">
      <a href="http://seekingalpha.com" class="footernav_logo"></a>
      <div class="footernav_boards">
          <a href="https://play.google.com/store/apps/details?id=com.seekingalpha.webwrapper" target="_blank" onclick="mobile_app_click()" class="google_play_mini_badge"></a>
          <a href="https://itunes.apple.com/us/app/seeking-alpha-portfolio/id552799694?mt=8" target="_blank" onclick="mobile_app_click()" class="app_store_mini_badge"></a>
      </div>
      <div class="cleaner"></div>
    </div>

     <div class="footernav_share_buttons">
   <a href="https://www.facebook.com/Seekingalpha" class="share_btn fb" sasource="footer" target="_blank"></a>
   <a href="https://twitter.com/SeekingAlpha" class="share_btn twitter" sasource="footer" target="_blank"></a>
   <a href="https://plus.google.com/+SeekingAlphaSA/" class="share_btn google" rel="publisher" sasource="footer" target="_blank"></a>
    </div>
    <div class="footernav_right">
      <div class="footernav_links">
        <a href="http://seekingalpha.com/leader-board/opinion-leaders" sasource="footer">Top Authors</a>&nbsp;&nbsp;|&nbsp;
        <a class="small_rss" href="http://seekingalpha.com/page/feeds" sasource="footer">&nbsp;&nbsp;&nbsp;&nbsp;RSS Feeds</a>&nbsp;&nbsp;|&nbsp;
        <a href="http://seekingalpha.com/sitemap" sasource="footer">Sitemap</a>&nbsp;&nbsp;|&nbsp;
        <a href="http://seekingalpha.com/page/about_us" sasource="footer">About Us</a>&nbsp;&nbsp;|&nbsp;
        <a href="http://seekingalpha.com/page/contact" sasource="footer">Contact Us</a>
      </div>
      <div class="footernav_more_links">
        <a href="http://seekingalpha.com/page/terms-of-use" sasource="footer">Terms of Use</a> |
        <a href="http://seekingalpha.com/page/privacy" sasource="footer">Privacy</a> |
        <a href="http://www.xignite.com" rel="nofollow" target="_blank">Xignite quote data</a> |
        <span>&#169; 2015 Seeking Alpha</span>
      </div>
      <div class="cleaner"></div>
    </div>
  </div>
  <div class="cleaner"></div>
</div>
<script>
  function mobile_app_click(){
    var location_pathname = location.pathname.split('/');
    var source = location.pathname.split('/')[1];

    if (source == '')
      source = 'home_page';
    else if (source == 'account' && location_pathname[2] == 'email_preferences')
      source = 'email_preferences';

    Mone.event('app_promo', 'footer_' + source, 'clicked');
  }
</script>

<div id="first_portfolio_unit_ref" style="display: none"> <div>
  <table id="first_portfolio_unit" style="padding-bottom: 7px !important; padding-top: 4px;">
    <thead><tr><th class="fs12">Symbol</th><th class="tr fs12">Price</th><th class="tr fs12">% Chg</th><th></th><th class="tc fs12">Remove</th><th></th></thead>
    <tbody>
        <tr id="first_portfolio_unit_cell0" class="mb10">
          <td style="width: 25%"><input id="first_portfolio_symbol_input0" class="fpu_input" placeholder="Type Ticker" maxlength="9"></td>
          <td style="width: 22%" id="first_portfolio_unit_symbol_price0" class="tr fs12">-</td>
          <td style="width: 20%" id="first_portfolio_unit_symbol_price_change0" class="tr fs12">-</td>
          <td style="width: 13%">&nbsp;</td>
          <td style="width: 7%" ><span id="first_portfolio_unit_symbol_price_remove_button0" class="remove_btn" onclick="SA.Units.Portfolio.First_portfolio_unit.removeSymbol('first_portfolio_unit_cell0')"></span></td>
          <td style="width: 13%">&nbsp;</td>
        </tr>
        <tr id="first_portfolio_unit_cell1" class="mb10 b-light-gray2">
          <td style="width: 25%"><input id="first_portfolio_symbol_input1" class="fpu_input" placeholder="Type Ticker" maxlength="9"></td>
          <td style="width: 22%" id="first_portfolio_unit_symbol_price1" class="tr fs12">-</td>
          <td style="width: 20%" id="first_portfolio_unit_symbol_price_change1" class="tr fs12">-</td>
          <td style="width: 13%">&nbsp;</td>
          <td style="width: 7%" ><span id="first_portfolio_unit_symbol_price_remove_button1" class="remove_btn" onclick="SA.Units.Portfolio.First_portfolio_unit.removeSymbol('first_portfolio_unit_cell1')"></span></td>
          <td style="width: 13%">&nbsp;</td>
        </tr>
        <tr id="first_portfolio_unit_cell2" class="mb10">
          <td style="width: 25%"><input id="first_portfolio_symbol_input2" class="fpu_input" placeholder="Type Ticker" maxlength="9"></td>
          <td style="width: 22%" id="first_portfolio_unit_symbol_price2" class="tr fs12">-</td>
          <td style="width: 20%" id="first_portfolio_unit_symbol_price_change2" class="tr fs12">-</td>
          <td style="width: 13%">&nbsp;</td>
          <td style="width: 7%" ><span id="first_portfolio_unit_symbol_price_remove_button2" class="remove_btn" onclick="SA.Units.Portfolio.First_portfolio_unit.removeSymbol('first_portfolio_unit_cell2')"></span></td>
          <td style="width: 13%">&nbsp;</td>
        </tr>
        <tr id="first_portfolio_unit_cell3" class="mb10 b-light-gray2">
          <td style="width: 25%"><input id="first_portfolio_symbol_input3" class="fpu_input" placeholder="Type Ticker" maxlength="9"></td>
          <td style="width: 22%" id="first_portfolio_unit_symbol_price3" class="tr fs12">-</td>
          <td style="width: 20%" id="first_portfolio_unit_symbol_price_change3" class="tr fs12">-</td>
          <td style="width: 13%">&nbsp;</td>
          <td style="width: 7%" ><span id="first_portfolio_unit_symbol_price_remove_button3" class="remove_btn" onclick="SA.Units.Portfolio.First_portfolio_unit.removeSymbol('first_portfolio_unit_cell3')"></span></td>
          <td style="width: 13%">&nbsp;</td>
        </tr>
        <tr id="first_portfolio_unit_cell4" class="mb10">
          <td style="width: 25%"><input id="first_portfolio_symbol_input4" class="fpu_input" placeholder="Type Ticker" maxlength="9"></td>
          <td style="width: 22%" id="first_portfolio_unit_symbol_price4" class="tr fs12">-</td>
          <td style="width: 20%" id="first_portfolio_unit_symbol_price_change4" class="tr fs12">-</td>
          <td style="width: 13%">&nbsp;</td>
          <td style="width: 7%" ><span id="first_portfolio_unit_symbol_price_remove_button4" class="remove_btn" onclick="SA.Units.Portfolio.First_portfolio_unit.removeSymbol('first_portfolio_unit_cell4')"></span></td>
          <td style="width: 13%">&nbsp;</td>
        </tr>
        <tr id="first_portfolio_unit_cell5" class="mb10 b-light-gray2">
          <td style="width: 25%"><input id="first_portfolio_symbol_input5" class="fpu_input" placeholder="Type Ticker" maxlength="9"></td>
          <td style="width: 22%" id="first_portfolio_unit_symbol_price5" class="tr fs12">-</td>
          <td style="width: 20%" id="first_portfolio_unit_symbol_price_change5" class="tr fs12">-</td>
          <td style="width: 13%">&nbsp;</td>
          <td style="width: 7%" ><span id="first_portfolio_unit_symbol_price_remove_button5" class="remove_btn" onclick="SA.Units.Portfolio.First_portfolio_unit.removeSymbol('first_portfolio_unit_cell5')"></span></td>
          <td style="width: 13%">&nbsp;</td>
        </tr>
        <tr id="first_portfolio_unit_cell6" class="mb10">
          <td style="width: 25%"><input id="first_portfolio_symbol_input6" class="fpu_input" placeholder="Type Ticker" maxlength="9"></td>
          <td style="width: 22%" id="first_portfolio_unit_symbol_price6" class="tr fs12">-</td>
          <td style="width: 20%" id="first_portfolio_unit_symbol_price_change6" class="tr fs12">-</td>
          <td style="width: 13%">&nbsp;</td>
          <td style="width: 7%" ><span id="first_portfolio_unit_symbol_price_remove_button6" class="remove_btn" onclick="SA.Units.Portfolio.First_portfolio_unit.removeSymbol('first_portfolio_unit_cell6')"></span></td>
          <td style="width: 13%">&nbsp;</td>
        </tr>
        <tr id="first_portfolio_unit_cell7" class="mb10 b-light-gray2">
          <td style="width: 25%"><input id="first_portfolio_symbol_input7" class="fpu_input" placeholder="Type Ticker" maxlength="9"></td>
          <td style="width: 22%" id="first_portfolio_unit_symbol_price7" class="tr fs12">-</td>
          <td style="width: 20%" id="first_portfolio_unit_symbol_price_change7" class="tr fs12">-</td>
          <td style="width: 13%">&nbsp;</td>
          <td style="width: 7%" ><span id="first_portfolio_unit_symbol_price_remove_button7" class="remove_btn" onclick="SA.Units.Portfolio.First_portfolio_unit.removeSymbol('first_portfolio_unit_cell7')"></span></td>
          <td style="width: 13%">&nbsp;</td>
        </tr>
    </tbody>
  </table>
</div>

<script>SA.Units.Portfolio.First_portfolio_unit.init('first_portfolio_symbol_input',8, 'transcript Register')</script>
</div>

<script type="text/javascript">
  Event.observe(window, 'scroll', run_article_end_mone);
  SA.Utils.Sharing.setSharingButtons('Article',ARTICLE_ID);

  if (location.href.match(/part=single/) == null){
    setRoadblockMandatoryTickers();
  	$('tab_cmd').show();
  	$('pag_cmd').show();
  }


  $('last_page_index').innerHTML = getPartialSlice(1,sliceSize,false,true,true);


  /* Roadblock test */
  function transcript_rb_show(){
    if (readCookie('user_email') && readCookie('user_email').length > 0 && !AlphaBox.isOpen) {
      SA.Utils.Popup.roadblock_login();
      createCookie('singlepageafterlogin',true);
      return;
    }

   //temporary remove iPad promo
   /*if (SA.Utils.Env.isIPad){
       ipad_roadblock_new();
   }*/
    else {
      if (document.viewport.getDimensions().height > 400){
        title = "Seeking Alpha transcribes 10,000+ earnings calls per year. For full, free access to these transcripts, please register and set up a portfolio in two easy steps:";
        createCookie('singlepageafterlogin',true);
        new RoadblockPopup('roadblock', 'transcript_register').roadblock_transcripts();
      }
    }
  }
  /* Roadblock test */
  function singlePageView(){
    if (SA.Data.User.loggedIn() || SA.Pages.Article.fromInsightCenters()) {
      transcriptRedirect("single");
    } else {
      transcript_rb_show();
    }
  }

  SeekingAlpha.Initializer.onDOMLoad(function(){

    /* Roadblock test */

    SA.Pages.Article.primary = "ddxs";
    SA.Pages.Article.init();

    rb = new roadblock('transcript');
    rb.additional_login_title = " for full transcript access";
    rb.register_show = transcript_rb_show;
    if (!readCookie("sessioncfr") && !SA.Pages.Article.skipFirstArticleRoadblock()) {
      if (!SA.Data.User.loggedIn() && !SA.Pages.Article.from_partner() && !SA.Pages.Article.fromEarningsCenter() && document.viewport.getDimensions().height > 400) {
        var firstPageTestValue = SA.Pages.Article.RoadblockTimeInFirstPageTest();
        if (location.href.match("page=([0-9]+)") && location.href.match("page=([0-9]+)")[1] > 1) {
          new RoadblockPopup('roadblock', 'transcript_register').roadblock_transcripts();
        } else if (firstPageTestValue) {
          setTimeout(function(){ new RoadblockPopup('roadblock', 'transcript_register').roadblock_transcripts(); }, firstPageTestValue * 1000);
        }
      }
    }
    if (!SA.Data.User.loggedIn() &&!SA.Pages.Article.fromInsightCenters()){
      SA.Pages.Article.hide_features_for_roadblock();
      if($('bottom_rta_unit')) {$('bottom_rta_unit').style.display = 'none';}
      if ($('tab_single_bottom')) {$('tab_single_bottom').show();}
    }
    /* Roadblock test */
  });

    SeekingAlpha.Initializer.AddAfterLoad(function(){
      SA.Pages.Article.articlePromo({"allSlugs":["ddxs"],"primarySlug":"ddxs"});
    });
</script>
    

<link href="//staticseekingalpha3.a.ssl.fastly.net/stylesheets/packaged/footer_packaged.css?h=1vogfdq.css" media="screen" rel="stylesheet" type="text/css" /><script type="text/javascript">
    window.jspell_urls = ["//staticseekingalpha3.a.ssl.fastly.net/javascripts/packaged/jspell_packaged.js?h=6a842a.js"]
    if(typeof (authors) == "undefined" || typeof (symbols) == "undefined")
        load_remote_script("//staticseekingalpha.a.ssl.fastly.net/javascripts/packaged/sa.js");
    if(is_users_cookie_exists() && !cookieExists('tops') && typeof(tops) == "undefined")
        load_remote_script("//staticseekingalpha1.a.ssl.fastly.net/javascripts/tops.js?h=uayop.js");
    Mone.renderedParams = {};
    SeekingAlpha.Initializer.AddAfterLoad(function(){SA.Performance.Utils.loadPrintStyle('//staticseekingalpha1.a.ssl.fastly.net/stylesheets/print.css?t=1439927516')});

    function switch_status(){
        new Ajax.Request('/authentication/get_menu', {
            asynchronous:true,
            method:'get',
            onComplete: function(transport) {
                eval(transport.responseJSON.code);
            }
        });
    }
    PortfolioNotification.run();
</script>

<noscript>
  <img src="http://b.scorecardresearch.com/p?c1=2&c2=8500672&cv=2.0&cj=1" width="0" height="0" />
</noscript>

<script type="text/javascript" src="//staticseekingalpha.a.ssl.fastly.net/pages/ads_399990.js"></script>

    <script crossorigin="use-credentials" src="//staticseekingalpha1.a.ssl.fastly.net/javascripts/packaged/footer_packaged.js?h=iyjmiy.js" type="text/javascript"></script>

<script type="application/ld+json">
    {
      "@context": "http://schema.org",
      "@type": "Organization",
      "name": "Seeking Alpha",
      "url": "http://seekingalpha.com",
      "logo": "//staticseekingalpha3.a.ssl.fastly.net/assets/social-50f1e86b5c7a0fda6a96bf2280e5360d.png",
      "sameAs" : [
        "https://plus.google.com/+SeekingAlphaSA",
        "https://twitter.com/SeekingAlpha",
        "https://www.facebook.com/Seekingalpha",
        "https://en.wikipedia.org/wiki/Seeking_Alpha",
        "https://www.linkedin.com/company/seeking-alpha"
      ]
    }
</script>
<script type="application/ld+json">
    {
       "@context": "http://schema.org",
       "@type": "WebSite",
       "url": "http://seekingalpha.com",
       "potentialAction": {
         "@type": "SearchAction",
         "target": "http://seekingalpha.com/search/?q={search_term_string}",
         "query-input": "required name=search_term_string"
       }
    }
</script>
<div id="symbol_data_script_container"></div>
<script type="text/javascript">
SeekingAlpha.Initializer.onDOMLoad(function(){
  if(SA.Pages && SA.Pages.Account && SA.Pages.Account.Portfolios){
    var a = SA.Pages.Account.Portfolios.alertsTab;
    SA.Pages.Account.Portfolios.alertsTab = function(b){if ($('ziignight_submit')) a(b);}
  }
});
if (/\/account\/portfolio/.test(location.href)) {document.getElementsByTagName("html")[0].style.overflow = "auto"};
if (!$("comment_form_wrapper") && /seekingalpha\.com\/currents\/post/.test(location.href) && $("ads_and_tools")){ $("ads_and_tools").style.position = 'absolute';$("ads_and_tools").style.top="60px";$("ads_and_tools").style.right="0";};
</script>
<style>
.portfolio_news #content_wrapper .left_content .market_currents ul#mc_news li  .bullet{* position: static;* padding:0 6px 6px 1px;}
</style>
<script>
if (/article\/2953766/.test(location.href) && $('etf_hub_promo')) setTimeout(function(){ $('etf_hub_promo').style.display = 'none'},150);
</script>


    <div class="cleaner"></div>
  </body>
</html>
